Does all postmenopausal bleeding need investigating?

Yes — even a single episode of spotting warrants a full workup, regardless of how light the bleeding was or how many years have passed since menopause. This is because approximately 1 in 10 women with postmenopausal bleeding has endometrial cancer, and earlier detection significantly improves outcomes. Endometrial cancer is Australia's most common gynaecological cancer, with around 3,300 new diagnoses per year. Its excellent five-year survival rate (approximately 83%) largely reflects early detection driven by the symptom of postmenopausal bleeding prompting timely investigation.

What does the transvaginal ultrasound measure and what does it mean?

A transvaginal ultrasound measures the maximum double-layer endometrial thickness (ET) in millimetres on a sagittal view. In postmenopausal women, an ET of 4 mm or less has a negative predictive value of approximately 99% for endometrial cancer (Smith-Bindman meta-analysis, JAMA 1998). This threshold — adopted by Cancer Australia 2024 and RANZCOG — means a thin endometrium and resolved bleeding can be managed with close clinical follow-up rather than immediate biopsy. However, any focal lesion on ultrasound (such as a polyp) requires further investigation by sonohysterography or hysteroscopy regardless of endometrial thickness.

What causes most postmenopausal bleeding?

Around 60% of postmenopausal bleeding is caused by atrophic vaginitis (also called genitourinary syndrome of menopause), where oestrogen withdrawal leads to thinning and friability of the vaginal and vulval mucosa. Endometrial atrophy accounts for a further 30%. Endometrial polyps contribute approximately 10%, and endometrial hyperplasia around 5–10%. Endometrial cancer is found in approximately 5–15% of women presenting with PMB. Cervical causes, hormonal therapy-related bleeding, and mistaken urinary or anorectal sources account for the remainder. Establishing the cause requires the full workup rather than making assumptions from the symptom pattern.

What is the treatment for atrophic vaginitis after PMB has been investigated?

Once endometrial cancer has been excluded through normal transvaginal ultrasound (and endometrial sampling if indicated), atrophic vaginitis is treated with vaginal oestrogen. First-line options include estradiol vaginal tablets (Vagifem 10 mcg, inserted nightly for two weeks then twice weekly for maintenance) or estriol cream (Ovestin). Both are PBS Authority Required Streamlined for genitourinary syndrome of menopause. Non-hormonal options — lubricants for intercourse and vaginal moisturisers (Replens, hyaluronic acid-based) — are used alongside or instead of vaginal oestrogen. Any return of bleeding while on vaginal oestrogen warrants a repeat workup.

What if my ultrasound was normal but the bleeding came back?

A normal transvaginal ultrasound (endometrial thickness 4 mm or less) does not permanently exclude endometrial pathology if bleeding recurs. Recurrent postmenopausal bleeding after an initially normal scan mandates a repeat workup, and hysteroscopy with direct visualisation and targeted biopsy is preferred over a second Pipelle for the second-round investigation. This is because the Pipelle has approximately a 25% false-negative rate for focal lesions such as polyps, which may not have been visible on the first ultrasound. Persistent or recurrent bleeding is never safely attributed to a benign cause on the basis of one normal investigation alone.

Postmenopausal bleeding

Postmenopausal bleeding: the AU general practice workup and pathway

By Dr HB Lo, FACRRM Reviewed 3 July 2026 8 min read

Postmenopausal bleeding (PMB) — any vaginal bleeding ≥12 months after the last period — requires cancer exclusion: approximately 10% of cases are endometrial cancer, Australia's most common gynaecological malignancy.

The first investigation is transvaginal ultrasound within two weeks. Endometrial thickness ≤4 mm carries approximately 99% negative predictive value for endometrial cancer. Thickness >4 mm, or persistent bleeding after a normal scan, warrants Pipelle or hysteroscopy sampling.

The most common cause (~60%) is atrophic vaginitis, which responds well to vaginal oestrogen — but cancer must be excluded before treating a benign cause.

Postmenopausal bleeding (PMB) is any vaginal bleeding occurring 12 or more months after the last menstrual period, or — in a woman on hormone therapy — any unexpected bleeding outside the expected withdrawal window for sequential combined preparations, or any bleeding after the first 6 months of continuous combined therapy.

PMB is a cancer alarm symptom. Approximately 10% of women who present with PMB — even a single spot — will be found to have endometrial cancer. Endometrial cancer is the most common gynaecological malignancy in Australia, with around 3,300 new diagnoses and 660 deaths annually per AIHW 2024. Its relatively favourable five-year survival (~83%) reflects the fact that most women present early, driven by the symptom of PMB. Any delay in investigation erodes this staging advantage.

The good news: most PMB (approximately 90%) is caused by benign conditions — atrophic vaginitis and endometrial atrophy account for the majority — but the only way to reach that reassurance responsibly is through a structured cancer-exclusion workup.

A. Core clinical — the AU general-practice framework

History

The history of PMB should establish:

Bleeding character: volume (spotting vs frank bleeding), duration, recurrence, relationship to intercourse (postcoital bleeding suggests cervical or atrophic aetiology).
Hormone therapy: current regimen (sequential vs continuous combined), adherence, recent dose changes. Unopposed oestrogen in a woman with a uterus is a red flag.
Tamoxifen use: breast cancer treatment greatly increases endometrial polyp, hyperplasia, and cancer risk.
Genitourinary syndrome of menopause (GSM) symptoms: vaginal dryness, dyspareunia, recurrent urinary tract infections. These support an atrophic substrate but do not exclude concurrent endometrial pathology.
Risk factors for endometrial cancer: obesity, type 2 diabetes, polycystic ovary syndrome, late menopause, nulliparity, unopposed oestrogen exposure.
Family history: Lynch syndrome (endometrial, colorectal, urothelial, ovarian cancers in first and second-degree relatives); BRCA pathogenic variants.
Mistaken source: explicitly establish whether blood was noted on a pad, in the toilet bowl (urinary or anorectal source possible), or on wiping after intercourse.

Examination

Speculum examination: inspect the vagina for atrophic changes (pale, thin, petechiae), discharge, and ulceration; inspect the cervix for polyps, ectropion, friability, and visible lesions. Perform cervical screening if due per the National Cervical Screening Program.
Bimanual examination: uterine size, mobility, and tenderness; adnexal mass.
Vulval inspection: lichen sclerosus, vulval intraepithelial neoplasia, vulval cancer, and atrophic changes.
Abdominal examination: pelvic or abdominal mass, organomegaly.

Investigations

Per Cancer Australia 2024, RANZCOG C-Gyn 38, and the Australian Cancer Plan 2024:

First-line — within two weeks of presentation:

Transvaginal ultrasound (TVUSS) MBS item 55070: measure maximum double-layer endometrial thickness (ET) in the sagittal plane.
- ET ≤4 mm: negative predictive value approximately 99% for endometrial cancer (Smith-Bindman JAMA 1998). Biopsy is not required if symptoms have resolved.
- ET >4 mm: endometrial sampling is required.
- Focal lesion (polyp, focal thickening): sonohysterography or hysteroscopy regardless of overall ET (blind Pipelle misses focal lesions approximately 25% of the time).
Endometrial sampling (Pipelle / Endocell biopsy or hysteroscopy with curettage): when ET >4 mm, when TVUSS shows a focal lesion, or when bleeding persists after a normal TVUSS.

Adjunct investigations: FBC and iron studies (anaemia); HbA1c (comorbid diabetes); cervical screening if due; MSU if urinary source is possible.

B. Investigating PMB — the endometrial thickness threshold and biopsy

The 4 mm threshold

The Smith-Bindman JAMA 1998 meta-analysis — pooled data from 35 studies involving over 5,000 women — established that an ET of 5 mm achieved 96% sensitivity for endometrial cancer. Subsequent Timmermans et al. BJOG 2010 data supported a 4 mm threshold in the PMB setting for higher sensitivity (~98%), and this is now the standard adopted by Cancer Australia 2024, RANZCOG, and the ACR Appropriateness Criteria 2020.

A threshold of 4 mm (rather than the historical 5 mm used in some centres) minimises the risk of missing a cancer in the setting of a symptom that carries a 1-in-10 cancer probability.

The Pipelle biopsy

Office Pipelle or Endocell endometrial sampling has a sensitivity of approximately 91% for endometrial carcinoma in postmenopausal women and approximately 99% specificity. However, it has a significant false-negative rate (~25%) for focal lesions including polyps and focal hyperplasia, and a 5–10% inadequate sample rate due to cervical stenosis. When the Pipelle sample is inadequate or returns normal tissue but bleeding continues, hysteroscopy with direct visualisation and targeted biopsy is required.

Hysteroscopy under gynaecology specialist care remains the definitive investigation for persistent bleeding, tamoxifen users (where TVUSS findings are notoriously unreliable due to subepithelial cystic change), and any case where clinical suspicion exceeds what the ultrasound or Pipelle has clarified.

Lynch syndrome consideration

Any confirmed endometrial cancer specimen should undergo mismatch repair (MMR) immunohistochemistry (IHC) to identify Lynch syndrome — a hereditary cancer syndrome that markedly elevates lifetime endometrial, colorectal, urothelial, and ovarian cancer risks. If MMR deficiency is identified, cascade germline testing via a Family Cancer Clinic should be arranged for the patient and family members. Cancer Council Australia provides patient-facing resources for hereditary cancer syndromes.

C. Managing the common benign causes

Atrophic vaginitis and genitourinary syndrome of menopause

Atrophic vaginitis (genitourinary syndrome of menopause, GSM) is the most common cause of PMB. Oestrogen withdrawal produces thinning, dryness, and friability of the vaginal and vulval mucosa, which bleeds easily with minor trauma (intercourse, examination, straining). It is treated with:

Vaginal oestrogen (first-line): estradiol vaginal tablets (Vagifem 10 mcg, inserted nightly for two weeks then twice weekly) or estriol vaginal cream (Ovestin) — PBS Authority Required Streamlined for GSM. Vaginal oestrogen has minimal systemic absorption at standard doses.
Non-hormonal options: lubricants (water- or silicone-based) for intercourse; vaginal moisturisers (Replens, hyaluronic acid-based) for ongoing dryness.
Breast cancer survivors: vaginal oestrogen in standard low doses has minimal systemic absorption and is generally acceptable for severe refractory GSM, but discussion with the treating oncologist is essential — particularly for women on aromatase inhibitors.

Any return of bleeding while on vaginal oestrogen is not attributed to treatment and requires a repeat workup.

Endometrial polyp

An endometrial polyp appears as a focal lesion on TVUSS or sonohysterography. Around 1–5% of postmenopausal endometrial polyps contain atypia or malignancy, so histological assessment after hysteroscopic polypectomy is obligatory.

Endometrial hyperplasia

Without atypia: managed with levonorgestrel-releasing intrauterine system (Mirena, PBS Authority Required) or oral medroxyprogesterone acetate, with repeat endometrial sampling at 6 months.
With atypia: approximately 30–40% harbour concurrent carcinoma at hysterectomy. Hysterectomy with bilateral salpingo-oophorectomy is standard. Fertility-sparing progestin management is an option for carefully selected younger women only, under tertiary gynaecological oncology supervision.

D. Australian operations

The two-week pathway

The Australian Cancer Plan 2024 formalises a two-week suspected-cancer pathway for PMB. The TVUSS should be requested with “postmenopausal bleeding — suspected endometrial cancer” annotation, and the referral to gynaecology annotated as urgent suspected cancer when ET exceeds 4 mm, a focal lesion is identified, or histology demonstrates hyperplasia with atypia or carcinoma.

MBS items

Consultations: MBS items 23/36/44. A Level C or D consultation is appropriate for the initial PMB assessment.
TVUSS: MBS item 55070 — request within two weeks of presentation.
Saline infusion sonohysterography: MBS item 55066 — when focal lesion suspected.
Pelvic MRI: MBS item 63461 — staging after histological diagnosis; specialist-ordered.
FBC: MBS item 65070.
Cervical screening: MBS item 73061.
Mental Health Treatment Plan: MBS items 2715/2717 — for cancer-related anxiety during workup.
GPCCMP (items 965/967): for chronic comorbidity management (obesity, diabetes) alongside PMB workup.
ATSI Health Assessment (item 715): includes proactive PMB enquiry and family cancer history.

PBS

Vaginal oestrogen (Vagifem, Ovestin, Premarin vaginal cream): PBS Authority Required Streamlined for genitourinary syndrome of menopause.
Medroxyprogesterone acetate (Provera): PBS Authority Required Streamlined for endometrial hyperplasia management.
Levonorgestrel-IUS (Mirena): PBS Authority Required for endometrial hyperplasia protection.

E. Special populations

Tamoxifen users: women taking tamoxifen for breast cancer treatment have a two- to three-fold elevated risk of endometrial polyps, hyperplasia, and cancer. Any PMB in a tamoxifen user requires urgent investigation. Importantly, routine ultrasound surveillance of asymptomatic tamoxifen users is not recommended — investigation is symptom-triggered. TVUSS is less reliable in tamoxifen users due to subepithelial cystic change mimicking endometrial thickening; direct hysteroscopy is often preferred for initial evaluation.

Women on hormone therapy: PMB should prompt review of the HRT regimen. Unexpected bleeding during the settling period of a new regimen (first 3–6 months for sequential, first 3 months for continuous combined) may be physiological; outside these windows, it requires investigation. Ensure adequate progestogen opposition for women with a uterus on systemic oestrogen.

Older women: the risk of endometrial cancer increases with age. Women in their 70s and 80s presenting with PMB still require the full workup — age alone does not reassure. Consideration of functional status, comorbidities, and goals of care is important in planning the extent of investigation and treatment if cancer is identified.

Aboriginal and Torres Strait Islander women: ATSI women have higher all-cancer mortality and face access barriers to timely investigation per AIHW 2024. Proactive PMB enquiry during ATSI Health Assessments (item 715), culturally safe explanation of the workup process, and close liaison with ACCHO services support equitable access.

Lynch syndrome families: women in Lynch syndrome families (MMR gene pathogenic variants) have a lifetime endometrial cancer risk of 40–60%. While routine surveillance ultrasound is not standard practice, proactive PMB education and family pedigree documentation are important. Any endometrial cancer in a family member warrants discussion of cascade testing.

When to escalate

Refer urgently (suspected-cancer pathway) when:

PMB is present — for TVUSS within two weeks.
ET exceeds 4 mm — for endometrial sampling and gynaecological oncology review.
A focal lesion is identified on TVUSS.
Atypical hyperplasia or endometrial carcinoma is confirmed on biopsy.
A visible lesion on the cervix, vagina, or vulva raises suspicion of cancer.
Postmenopausal pyometra (offensive discharge, uterine tenderness, distended uterus on TVUSS).
Pelvic mass identified on examination or imaging.

Refer to emergency when heavy bleeding causes haemodynamic compromise.

What this article is and is not

This is general health information drawn from Australian clinical guidelines — Cancer Australia 2024, RANZCOG C-Gyn 38, and the Australian Cancer Plan 2024 — and peer-reviewed evidence on the endometrial thickness threshold. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about investigation timing, endometrial sampling, and referral are made with your own GP and treating gynaecologist.

For consumer resources: Jean Hailes for Women’s Health, Cancer Council Australia — Uterine cancer, HealthDirect, and Australasian Menopause Society.

Sources cited

Frequently asked questions

Does all postmenopausal bleeding need investigating?

Yes — even a single episode of spotting warrants a full workup, regardless of how light the bleeding was or how many years have passed since menopause. This is because approximately 1 in 10 women with postmenopausal bleeding has endometrial cancer, and earlier detection significantly improves outcomes. Endometrial cancer is Australia's most common gynaecological cancer, with around 3,300 new diagnoses per year. Its excellent five-year survival rate (approximately 83%) largely reflects early detection driven by the symptom of postmenopausal bleeding prompting timely investigation.
What does the transvaginal ultrasound measure and what does it mean?

A transvaginal ultrasound measures the maximum double-layer endometrial thickness (ET) in millimetres on a sagittal view. In postmenopausal women, an ET of 4 mm or less has a negative predictive value of approximately 99% for endometrial cancer (Smith-Bindman meta-analysis, JAMA 1998). This threshold — adopted by Cancer Australia 2024 and RANZCOG — means a thin endometrium and resolved bleeding can be managed with close clinical follow-up rather than immediate biopsy. However, any focal lesion on ultrasound (such as a polyp) requires further investigation by sonohysterography or hysteroscopy regardless of endometrial thickness.
What causes most postmenopausal bleeding?

Around 60% of postmenopausal bleeding is caused by atrophic vaginitis (also called genitourinary syndrome of menopause), where oestrogen withdrawal leads to thinning and friability of the vaginal and vulval mucosa. Endometrial atrophy accounts for a further 30%. Endometrial polyps contribute approximately 10%, and endometrial hyperplasia around 5–10%. Endometrial cancer is found in approximately 5–15% of women presenting with PMB. Cervical causes, hormonal therapy-related bleeding, and mistaken urinary or anorectal sources account for the remainder. Establishing the cause requires the full workup rather than making assumptions from the symptom pattern.
What is the treatment for atrophic vaginitis after PMB has been investigated?

Once endometrial cancer has been excluded through normal transvaginal ultrasound (and endometrial sampling if indicated), atrophic vaginitis is treated with vaginal oestrogen. First-line options include estradiol vaginal tablets (Vagifem 10 mcg, inserted nightly for two weeks then twice weekly for maintenance) or estriol cream (Ovestin). Both are PBS Authority Required Streamlined for genitourinary syndrome of menopause. Non-hormonal options — lubricants for intercourse and vaginal moisturisers (Replens, hyaluronic acid-based) — are used alongside or instead of vaginal oestrogen. Any return of bleeding while on vaginal oestrogen warrants a repeat workup.
What if my ultrasound was normal but the bleeding came back?

A normal transvaginal ultrasound (endometrial thickness 4 mm or less) does not permanently exclude endometrial pathology if bleeding recurs. Recurrent postmenopausal bleeding after an initially normal scan mandates a repeat workup, and hysteroscopy with direct visualisation and targeted biopsy is preferred over a second Pipelle for the second-round investigation. This is because the Pipelle has approximately a 25% false-negative rate for focal lesions such as polyps, which may not have been visible on the first ultrasound. Persistent or recurrent bleeding is never safely attributed to a benign cause on the basis of one normal investigation alone.

Source quality

Sources grouped by evidence tier. AU primary tier first; international where AU is silent or lagging; named-author reconstruction where guidelines have not yet caught up. How tiers work.

T1 AU primary 10 sources
T2 International primary 1 source
- NICE NG12 — Suspected cancer: recognition and referral
T3 Named-author reconstruction 1 source
- Smith-Bindman R et al. — Endovaginal ultrasound to exclude endometrial cancer (JAMA 1998)